These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 18941747

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats.
    Choi JS, Jo BW.
    Int J Pharm; 2004 Aug 06; 280(1-2):221-7. PubMed ID: 15265561
    [Abstract] [Full Text] [Related]

  • 28. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.
    Kemper EM, Cleypool C, Boogerd W, Beijnen JH, van Tellingen O.
    Cancer Chemother Pharmacol; 2004 Feb 06; 53(2):173-8. PubMed ID: 14605863
    [Abstract] [Full Text] [Related]

  • 29. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
    Malingré MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Ten Bokkel Huinink WW, Schellens JH.
    Br J Cancer; 2001 Jan 05; 84(1):42-7. PubMed ID: 11139311
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats.
    Jin J, Bi H, Hu J, Zhong G, Zhao L, Huang Z, Huang M.
    Biopharm Drug Dispos; 2010 May 05; 31(4):264-8. PubMed ID: 20437465
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. PEG conjugated N-octyl-O-sulfate chitosan micelles for delivery of paclitaxel: in vitro characterization and in vivo evaluation.
    Qu G, Yao Z, Zhang C, Wu X, Ping Q.
    Eur J Pharm Sci; 2009 May 12; 37(2):98-105. PubMed ID: 19429416
    [Abstract] [Full Text] [Related]

  • 34. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
    Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ.
    Cancer Chemother Pharmacol; 2009 May 12; 63(6):1049-63. PubMed ID: 18791718
    [Abstract] [Full Text] [Related]

  • 35. Stabilized micelles as delivery vehicles for paclitaxel.
    Yoncheva K, Calleja P, Agüeros M, Petrov P, Miladinova I, Tsvetanov C, Irache JM.
    Int J Pharm; 2012 Oct 15; 436(1-2):258-64. PubMed ID: 22721848
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor.
    Li C, Newman RA, Wu QP, Ke S, Chen W, Hutto T, Kan Z, Brannan MD, Charnsangavej C, Wallace S.
    Cancer Chemother Pharmacol; 2000 Oct 15; 46(5):416-22. PubMed ID: 11127947
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.